Skip to content
10-Q

Quarterly Report

Bio-Rad Laboratories, Inc. BIO BIO-B

0000012208-25-000026

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $1.2B
Long Term Debt Q1 2025 · Dec 31, 2024 $1.2B
Short Term Investments Q1 2025 · Mar 31, 2025 $1.14B
Short Term Investments Q1 2025 · Dec 31, 2024 $1.18B
Current Liabilities Q1 2025 · Mar 31, 2025 $506.6M
Current Liabilities Q1 2025 · Dec 31, 2024 $467.8M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.85B
Total Liabilities Q1 2025 · Dec 31, 2024 $2.79B
Current Assets Q1 2025 · Mar 31, 2025 $3.04B
Current Assets Q1 2025 · Dec 31, 2024 $3.03B
Total Assets Q1 2025 · Mar 31, 2025 $9.53B
Total Assets Q1 2025 · Dec 31, 2024 $9.36B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $488.1M
Cash And Equivalents restated Q1 2025 · Mar 31, 2024 $433.3M
Shares Diluted Q1 2025 · Mar 31, 2024 28.54M sh
Stock Repurchased restated Q1 2025 · Mar 31, 2024 $4.7M
Capex restated Q1 2025 · Mar 31, 2024 $40.2M
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 $69.8M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 $9.05B
Stockholders Equity restated Q1 2025 · Dec 31, 2023 $8.74B
Eps Diluted Q1 2025 · Mar 31, 2024 $13.45
Eps Basic Q1 2025 · Mar 31, 2024 $13.46
Sga Expense restated Q1 2025 · Mar 31, 2024 $214.9M
Rd Expense restated Q1 2025 · Mar 31, 2024 $66.4M
Net Income restated Q1 2025 · Mar 31, 2024 $383.9M
Operating Income restated Q1 2025 · Mar 31, 2024 $44.6M
Gross Profit restated Q1 2025 · Mar 31, 2024 $325.9M
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $284.9M
Revenue restated Q1 2025 · Mar 31, 2024 $610.8M